About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Drug Combo To Treat Adult Sarcoma Gets FDA Approval

by Bidita Debnath on November 5, 2016 at 9:53 PM
Font : A-A+

 New Drug Combo To Treat Adult Sarcoma Gets FDA Approval

In the United States, there are approximately 15,000 sarcoma cases annually, comprising more than 60 types of soft tissue sarcomas and 20 types of bony sarcomas.

Patients with advanced sarcomas that have metastasized or that cannot be cured with surgery are commonly treated with doxorubicin chemotherapy. Recent findings show that adding the new targeted antibody olaratumab (Lartruvo) in combination with doxorubicin improves progression-free survival and overall survival in patients with advanced sarcomas.

Advertisement


Oncologist Dr. Arun Singh is an assistant professor and co-director of the sarcoma program in the division of hematology/oncology in the David Geffen School of Medicine at UCLA. Dr. Singh's research is focused on developing novel therapies for patients with sarcomas.

Dr. Singh can discuss clinical trials for sarcoma patients and immunotherapeutic approaches for managing these diseases. He can also explain what the recent FDA approval of olaratumab (Lartruvo) means for sarcoma patients and how this recent decision could change the way oncologists use traditional methods such as chemotherapy, radiation therapy and surgery to treat people with the disease.
Advertisement

"The Food and Drug Administration's recent approval of this sarcoma combo treatment happened during an exciting time," says Singh. "I'm currently an investigator of a large ongoing phase 3 clinical trial, and if the results are positive, the findings will continue to advance the standard of care for patients with advanced soft tissue sarcomas."

UCLA's Jonsson Comprehensive Cancer Center has more than 450 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In August 2016, the Jonsson cancer center ranked among the top five cancer centers nationwide by U.S. News & World Report.

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Clinical Trials - Different Phases of the trial Signature Drug Toxicity Drugs Banned in India Rhabdomyosarcoma Liposarcoma Fallopian Tube Cancer 

Most Popular on Medindia

Vent Forte (Theophylline) Nutam (400mg) (Piracetam) Drug Interaction Checker Blood Donation - Recipients Drug - Food Interactions The Essence of Yoga Blood Pressure Calculator Hearing Loss Calculator Color Blindness Calculator Noscaphene (Noscapine)
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Drug Combo To Treat Adult Sarcoma Gets FDA Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests